• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Shionogi and Ferrer sign an agreement for the promotion in Spain of Rizmoic® (naldemedine), a treatment for opioid-induced constipation

    PRESS RELEASE

    SHIONOGI AND MOLTENI CONCLUDE A CONTRACT FOR THE COMMERCIALIZATION OF RIZMOIC®

    BUSINESSWIRE

    Determination of Regulatory Review Period for Purposes of Patent Extension

    FEDERAL REGISTER

    Shionogi Concludes a Contract for the Commercialization of Rizmoic®

    BUSINESSWIRE

    Sandoz to commercialize Shionogi`s Rizmoic in Germany, UK and Netherlands

    PHARMABIZ

    Shionogi NV`s Rizmoic (Naldemedine tosilate) Receives Approval in Europe

    EMA

    Two years following US approval, Japan’s Shionogi wins EU green light

    ENDPTS

    Shionogi Regains Full Rights to Symproic® (naldemedine) in the US

    PRESS RELEASE

    Fifty-Two Week Safety Study on Symproic® (naldemedine) for (OIC)

    PRESS RELEASE

    Shionogi & Purdue Pharma Announce U.S. Availability of Symproic® (naldemedine)

    FDA Approves Symproic® (naldemedine) Once-Daily Tablets C-II

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.